JAGX Jaguar Health Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAGX

Price (delayed)

$8.91

Market cap

$3.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3,926

Enterprise value

$13.13M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 24

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal ...

Highlights
JAGX's quick ratio has surged by 125% year-on-year and by 8% since the previous quarter
The EPS has soared by 77% YoY and by 57% QoQ
The equity has soared by 147% QoQ but it fell by 17% YoY
Jaguar Health's gross profit has surged by 137% YoY but it has decreased by 9% QoQ
JAGX's gross margin is down by 3.3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.jaguar.health
Peers: ZTS LFVN COCP

Key stats

What are the main financial stats of JAGX

JAGX stock price

How has the Jaguar Health stock price performed over time
Intraday
-74.14%
1 week
155.3%
1 month
-31.51%
1 year
-99.16%
YTD
-98.18%
QTD
-80.2%

Financial performance

How have Jaguar Health's revenue and profit performed over time
Revenue
$27.82M
Gross profit
$22.89M
Operating income
-$25.9M
Net income
-$36.4M
Gross margin
82.3%
Net margin
-130.9%
Jaguar Health's gross profit has surged by 137% YoY but it has decreased by 9% QoQ
The company's revenue has surged by 136% YoY but it fell by 6% QoQ
JAGX's operating margin has soared by 67% YoY but it is down by 4.6% from the previous quarter
JAGX's net margin has surged by 62% year-on-year but it is down by 13% since the previous quarter

Price vs fundamentals

How does JAGX's price correlate with its fundamentals

Growth

What is Jaguar Health's growth rate over time

Valuation

What is Jaguar Health stock price valuation
P/E
N/A
P/B
0.05
P/S
0.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
The EPS has soared by 77% YoY and by 57% QoQ
The equity has soared by 147% QoQ but it fell by 17% YoY
The price to book (P/B) is 92% lower than the 5-year quarterly average of 2.6
The company's revenue has surged by 136% YoY but it fell by 6% QoQ
The price to sales (P/S) is 98% lower than the 5-year quarterly average of 3.1 and 65% lower than the last 4 quarters average of 0.2

Efficiency

How efficient is Jaguar Health business performance
The return on invested capital has dropped by 157% year-on-year and by 60% since the previous quarter
The company's return on assets has shrunk by 71% YoY and by 14% QoQ
The ROS has soared by 63% YoY but it fell by 13% QoQ

Dividends

What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAGX.

Financial health

How did Jaguar Health financials performed over time
JAGX's total assets is 17% greater than its total liabilities
JAGX's quick ratio has surged by 125% year-on-year and by 8% since the previous quarter
JAGX's total liabilities is down by 45% from the previous quarter and by 29% YoY
JAGX's debt is 152% greater than its equity
The equity has soared by 147% QoQ but it fell by 17% YoY
JAGX's debt has dropped by 51% since the previous quarter and by 45% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.